411 - Phase 1/2 Trial of an Investigational Herpes Zoster Vaccine with CpG 1018® Adjuvant and Shingrix in Healthy Adults 50 to 69 Years of Age

Presenting Author(s)

• 

  Oliver Medzihradsky, MD MPH MS

  Senior Medical Director
  Dynavax Technologies
  Emeryville, California, United States

Co-Author(s)

• RG

  Rachel Graham, MBBS

  Innovate Clinical Research
  Waitara, New South Wales, Australia
• PN

  Paul Nguyen, MBBS

  Emeritus Research Melbourne
  Camberwell, Victoria, Australia
• DS

  Deon Smith, MBChB

  Canopy Clinical Research Northern Beaches
  Brookvale, New South Wales, Australia
• PB

  Paul Bird, BMed, PhD

  Emeritus Research Sydney
  Botany, New South Wales, Australia
• JC

  John D. Campbell, PhD

  Senior Director and Platform Leader
  Dynavax Technologies
  Emeryville, California, United States
• ME

  Mohamed El Idrissi, MSc

  Biostatistician
  Dynavax Technologies
  Brussels, Brussels Hoofdstedelijk Gewest, Belgium
• AO

  Ade Odueyungbo, PhD

  Senior Director
  Dynavax Technologies
  Emeryville, California, United States
• OH

  Ouzama Henry, MD MSc

  Vice President
  Dynavax Technologies
  Emeryville, California, United States
• 

  Robert Janssen, MD

  Chief Medical Officer
  Dynavax Technologies Corporation
  Emeryville, California, United States